GLPG5101

Cell therapy

DiscontinuedCD19
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-02-23), as a strategic decision by the sponsor

Galapagos (now Lakefront Biotherapeutics) wound down its cell therapy business after a strategic review and terminated the Phase 1/2 ATALANTA-1 study of GLPG5101 early. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 17 of them ahead of this one.

This drug's own stage for Non-Hodgkin Lymphoma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
GLPG5101: this drugDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Inebilizumab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Reliable signal
NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4)
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
ObinutuzumabPhase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Budoprutug
Phase 2(overall)
Monoclonal antibodyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT819
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-T
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-319
Phase 1(overall)
Antibody–drug conjugateCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-519
Phase 1(overall)
—CD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
HRS-3738Phase 1Small moleculeCereblon (CRBN)not yet gradedNo reviewed efficacy summary in this indication
IC19 CAR-T
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
UTAA09
Phase 1(overall)
Cell therapyCD19
Weak signal(overall)
No reviewed efficacy summary in this indication
ZM001
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Vispacabtagene Regedleucel
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.